MedTrace Logo

Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers

NCT00164762 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2007-10-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether the addition of zidovudine (ZDV) and lamivudine (3TC) at the onset of labor and for up to seven days postpartum to single-dose nevirapine (NVP) is associated with a lower prevalence of NVP-resistant HIV compared to single-dose NVP without ZDV+3TC.

Conditions

  • HIV Infections

Sponsors & Collaborators

Principal Investigators

  • Sherry L Farr, PhD · Centers for Disease Control and Prevention

  • Denise J Jamieson, MD, MPH · Centers for Disease Control and Prevention

  • Charles Van der Horst, MD · University of North Carolina, Chapel Hill

  • Peter Kazembe, MB ChB · Kamuzu Central Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Completion
2006-11-30

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00164762 on ClinicalTrials.gov